Comparative Effectiveness of Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis: A Propensity-Matched Cohort Analysis

被引：0
|
作者：
Kochhar, Gursimran S. [1 ]
Khataniar, Himsikhar [1 ]
Hashash, Jana G. [2 ]
Farraye, Francis A. [2 ]
Desai, Aakash [3 ]
机构：
[1] Allegheny Gen Hosp, Pittsburgh, PA USA
[2] Mayo Clin, Jacksonville, FL USA
[3] Mayo Clin, Pittsburgh, PA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001033780.31178.74
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1103
引用
收藏
页码：S780 / S781
页数：2
相关论文
共 50 条
  • [1] Comparative Effectiveness of Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis: A Propensity-Matched Cohort Analysis
    Kochhar, Gursimran S.
    Khataniar, Himsikhar
    Hashash, Jana G.
    Tabaku, Fjona
    Regueiro, Miguel
    Farraye, Francis A.
    Desai, Aakash
    INFLAMMATORY BOWEL DISEASES, 2024,
  • [2] Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis
    Daungsupawong, Hinpetch
    Wiwanitkit, Viroj
    INFLAMMATORY BOWEL DISEASES, 2025,
  • [3] Comparative Effectiveness of Upadacitinib and Tofacitinib in Ulcerative Colitis: A US Propensity-Matched Cohort Study
    Kochhar, Gursimran S.
    Khataniar, Himsikhar
    Jairath, Vipul
    Farraye, Francis A.
    Desai, Aakash
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (12): : 2471 - 2479
  • [4] Comparative Effectiveness of First-Line Infliximab and Vedolizumab in Patients with Early Ulcerative Colitis
    Hemed, A. Rozenfeld
    Cohen, N. A.
    Green, O.
    Hirsch, A.
    Thurm, T.
    Ron, Y.
    Fishman, S.
    Leibovitzh, H.
    Maharshak, N.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1476 - I1477
  • [5] COST-EFFECTIVENESS OF VEDOLIZUMAB, INFLIXIMAB, AND ADALIMUMAB AS FIRST-LINE THERAPY FOR ULCERATIVE COLITIS
    Beilman, Candace L.
    Fedorak, Richard N.
    Halloran, Brendan P.
    GASTROENTEROLOGY, 2018, 154 (06) : S450 - S450
  • [6] Vedolizumab as the First-Line of Biologicals for Pediatric Patients With Ulcerative Colitis
    Kakiuchi, Toshihiko
    Yoshiura, Masato
    CLINICAL THERAPEUTICS, 2022, 44 (07) : 1028 - 1032
  • [7] Cytomegalovirus Infection in Patients With Ulcerative Colitis: A Propensity-Matched Analysis
    Desai, Jiten
    Patel, Kirtenkumar
    Patel, Amitkumar
    Kavani, Himanshu
    Shah, Vraj
    Patel, Henalkumar
    Patel, Krunalkumar
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S419 - S420
  • [8] Ulcerative Colitis Therapy: Vedolizumab as a First-line Biologic Agent?
    Metzger, Leandra
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2022, 60 (03): : 274 - 276
  • [9] Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy
    Salcedo, Jonathan
    Hill-McManus, Daniel
    Hardern, Chloe
    Opeifa, Oyin
    Viti, Raffaella
    Siviero, Ludovica
    Roscini, Antonio Saverio
    Di Martino, Gennaro
    PHARMACOECONOMICS-OPEN, 2024, 8 (05) : 701 - 714
  • [10] Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis
    Faleck, D.
    Shashi, P.
    Meserve, J.
    Rahal, M.
    Kadire, S.
    Tran, G.
    Weiss, A.
    Winters, A.
    Chablaney, S.
    Aniwan, S.
    Koliani-Pace, J. L.
    Kochhar, G.
    Boland, B.
    Singh, S.
    Hirten, R.
    Shmidt, E.
    Lasch, K.
    Luo, M.
    Bohm, M.
    Sagi, S. V.
    Fischer, M.
    Hudesman, D.
    Chang, S.
    Lukin, D.
    Sultan, K.
    Swaminath, A.
    Gupta, N.
    Siegel, C. A.
    Shen, B.
    Sandborn, W. J.
    Sands, B. E.
    Colombel, J-F.
    Kane, S.
    Loftus, E. V.
    Dulai, P. S.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S19 - S19
12345